# Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

> **NCT03062800** · PHASE2 · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 232 (estimated)

## Conditions studied

- Advanced Nsclc

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** pemetrexed
- **DRUG:** cisplatin
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT03062800
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2020-12
- **Final completion:** 2021-11
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062800, "Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03062800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*